Atlas Trials

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Clinical trial NCT03768570 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03768570
Sponsor
Canadian Cancer Trials Group
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2019-10-25
Primary completion
2026-10-31
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.